Diabetes drug repurposed in fight against leading cause of blindness
NCT ID NCT07174687
Summary
This study is testing if a daily pill called dapagliflozin, already used for diabetes, can slow the progression of an advanced form of age-related macular degeneration (AMD) called geographic atrophy (GA). About 70 adults with GA will take either the drug or a placebo for one year to see if it reduces the growth of eye lesions and preserves vision. The goal is to find a new treatment to control this common cause of vision loss.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GEOGRAPHIC ATROPHY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Washington University
RECRUITINGSt Louis, Missouri, 63110, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.